PD-L2 Antibody

SKU: orb1239861

Description

PD-L2 Antibody

Images & Validation

• Tested Applications: ELISA, IF, IHC-P, WB
• Reactivity: Human, Mouse
• Predicted Reactivity: Rat

Key Properties

• Antibody Type: Primary Antibody
• Clonality: Polyclonal
• Isotype: IgG
• Immunogen: Anti-PD-L2 antibody (orb1239861) was raised against a peptide corresponding to 16 amino acids near the center of human PD-L2. The immunogen is located within amino acids 140-190 of PD-L2.
• Target: PDCD1LG2
• Molecular Weight: Predicted: 31kDObserved: 29 kD
• Purification: PD-L2 Antibody is affinity chromatography purified via peptide column.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Form/Appearance: Liquid
• Buffer/Preservatives: PD-L2 Antibody is supplied in PBS containing 0.02% sodium azide.
• Concentration: 1 mg/mL
• Disclaimer: For research use only

Alternative Names

PD-L2 Antibody: B7DC, Btdc, PDL2, CD273, PD-L2, PDCD1L2, bA574F11.2, B7DC, Programmed cell death 1 ligand 2, Butyrophilin B7-DC, PD-1 ligand 2

Western Blot Validation in Human Raji Cell Lysate. Loading: 15 µg of lysates per lane. Antibodies: PD-L2 orb1239861 (A: 0.5 µg/mL and B: 1 µg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Independent Antibody Validation (IAV) via Protein Expression Profile in Human and Mouse Cell Lines. Loading: 15 µg of lysates per lane. Antibodies: PD-L2, orb1239861 (4 µg/mL), competitor antibody (4 µg/mL), and beta-actin (1 µg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

KO Validation in HeLa Cells. Loading: 15 µg of HeLa WT cell lysates or PD-L2 KO cell lysates. Antibodies: PD-L2, orb1239861 (4 µg/mL) and beta-actin orb1240312 (1 µg/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat Anti-Rabbit IgG HRP conjugate at 1:10000 dilution.

KO Validation in HeLa Cells. Loading: 15 µg of HeLa WT cell lysates or PD-L2 KO cell lysates. Antibodies: PD-L2, orb1239861 (4 µg/mL) and beta-actin orb1240312 (1 µg/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat Anti-Rabbit IgG HRP conjugate at 1:10000 dilution.

Immunohistochemistry Validation of PD-L2 in Mouse Brain Tissue. Immunohistochemical analysis of paraffin-embedded mouse brain tissue using anti-PD-L2 antibody (orb1239861) at 2.5 µg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

Immunofluorescence Validation of PD-L2 in Mouse Brain Tissue. Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse brain cells labeling PD-L2 with orb1239861 at 20 µg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).

Immunohistochemistry Validation of PD-L2 in Mouse Brain Tissue. Immunohistochemical analysis of paraffin-embedded mouse brain tissue using anti-PD-L2 antibody (orb1239861) at 2.5 µg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

Immunofluorescence Validation of PD-L2 in Mouse Brain Tissue. Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse brain tissue labeling PD-L2 with orb1239861 at 20 µg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).

Immunohistochemistry Validation of PD-L2 in Lung Tumor of Mice (Kao et al., 2015). Protein analysis for PD-L2 (E-H) by immunohistochemistry with anti-PD-L2 antibodies in mice lung tumors. hMUC1.Tg mice were induced with lung adenoma and then treated with concurrent or sequential cisplatin/radiotherapy. PD-L2 expression level at week 41 after treatment was similar in control and treatment groups.

Regulated Expression Validation of PD-L2 in Mice with Melanoma Tumor (Knox et al., 2019). Immunoblot analysis of PD-L2 expression with anti-PD-L2 (orb1239861) antibodies. PD-L2 expression was up-regulated by anti-PD1 antibody treatment whereas it was reduced by Next A alone or combination treatment (anti-PD1 antibody + NextA).

Quick Database Links

Gene Symbol

PDCD1LG2

UniProt

Q9BQ51

RefSeq (Protein):NP_079515